Completion of non-exclusive framework agreements for the provision of services of specialized outpatient Palliatiw care (SAPW) according to § 37 b SGB W iwm § 132 d SGB W (open-house model).
Completion of non-exclusive framework agreements for the provision of services of specialized outpatient palliative care (SAPV) according to § 37 b SGB V (open-house model).
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB V for pharmaceuticals with the active substance fosfomycin (ATC: J01XX01) as part of a so-called open-house model.
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB V for pharmaceuticals with the active substance Lenograstim (ATC: L03AA10) as part of a so-called open-house model.
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB W for pharmaceuticals with the active substance fusidic acid (ATC: D06AX01) as part of a so-called open-house model.
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB V for pharmaceuticals with the active substance lacosamide (ATC: N03AX18) as part of a so-called open-house model.
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB V for pharmaceuticals with the active substance Bupropion (ATC: N06AX12) as part of a so-called open-house model.
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB V for pharmaceuticals with the active ingredient Valsartan + Amlodipin (ATC: C09DB01) as part of a so-called open-house model.
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB W for pharmaceuticals with the active substance enoxaparin (ATC: B01AB05) as part of a so-called open-house model.